3-amino-1-phenyl-4,5-dihydro-1h-pyrazol-5-one profile

3-amino-1-phenyl-4,5-dihydro-1H-pyrazol-5-one: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	77794
CHEMBL ID	1872892
MeSH ID	M0488887

Synonyms (48)

Synonym
AC-7642
5-amino-2-phenyl-2,4-dihydro-pyrazol-3-one
nsc 3336
mls002637685 ,
nsc3336
nsc-3336
4149-06-8
3-amino-1-phenyl-2-pyrazolin-5-one
3h-pyrazol-3-one, 5-amino-2,4-dihydro-2-phenyl-
SDCCGMLS-0066224.P001
TIMTEC1_001023
einecs 223-974-0
brn 0153681
2,4-dihydro-5-amino-2-phenyl-3h-pyrazol-3-one
ai3-61273
3h-pyrazol-3-one, 2,4-dihydro-5-amino-2-phenyl-
NCGC00174876-01
5-amino-2-phenyl-2,4-dihydro-3h-pyrazol-3-one
STK387497
HMS1536O11
A1034
inchi=1/c9h9n3o/c10-8-6-9(13)12(11-8)7-4-2-1-3-5-7/h1-5h,6h2,(h2,10,11)
5-amino-2-phenyl-4h-pyrazol-3-one
lpovzhyarsaviz-uhfffaoysa-
smr001547208
BRD-K03635798-001-01-9
3-amino-1-phenyl-4,5-dihydro-1h-pyrazol-5-one
AKOS000119164
HMS3078O03
3-amino-1-phenyl-1h-pyrazol-5(4h)-one
CHEMBL1872892
1-phenyl-3-amino-4,5-dihydropyrazol-5-on
LPOVZHYARSAVIZ-UHFFFAOYSA-N
5-amino-2-phenyl-2,4-dihydro-3h-pyrazol-3-one #
TS-02423
5-amino-2,4-dihydro-2-phenyl-3h-pyrazol-3-one
mfcd00003137
1-phenyl-3-amino-2-pyrazolin-5-one
F0347-2152
DTXSID50194382
SR-01000597229-1
sr-01000597229
EN300-19053
F53363
CS-0186756
Z104472454
nsc823724
nsc-823724

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
glp-1 receptor, partial	Homo sapiens (human)	Potency	0.7943	0.0184	6.8060	14.1254	AID624417
apical membrane antigen 1, AMA1	Plasmodium falciparum 3D7	Potency	6.3096	0.7079	12.1943	39.8107	AID720542
67.9K protein	Vaccinia virus	Potency	3.1623	0.0001	8.4406	100.0000	AID720579
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	12.5893	0.3548	28.0659	89.1251	AID504847
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	31.6228	0.0501	27.0736	89.1251	AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay ID	Title	Year	Journal	Article
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (22.22)	29.6817
2010's	5 (55.56)	24.3611
2020's	2 (22.22)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1
Encephalitis, Polio [description not available]	2.06	1
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	2.06	1
Plasmodium falciparum Malaria [description not available]	2.1	1
Malaria, Falciparum Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.	2.1	1

3-amino-1-phenyl-4,5-dihydro-1h-pyrazol-5-one

Description

Cross-References

Synonyms (48)

Protein Targets (5)

Potency Measurements

Bioassays (15)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.04

Study Types

3-amino-1-phenyl-4,5-dihydro-1h-pyrazol-5-one

Description

Cross-References

Synonyms (48)

Protein Targets (5)

Potency Measurements

Bioassays (15)

Research

Studies (9)

Market Indicators

Research Demand Index: 12.04

Study Types

Related Conditions (6)